{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-258537","form_type":"8-K","ticker":"FBRX","cik":"0001419041","company_name":"Forte Biosciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:08.400749+00:00","generated_at":"2026-05-30T00:23:37.535579+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Forte Biosciences advances FB102 into celiac trial; Q3 net loss $8.4M","bullets":["Dosing begun in celiac disease trial; topline data expected Q2 2025.","Phase 1 healthy-volunteer study of FB102 completed with good safety and NK cell reduction.","Q3 R&D expense $5.9M vs $6.4M YoY; net loss per share $(4.54) vs $(6.57).","Cash and equivalents $16.4M as of Sept 30, 2024; shares outstanding 1.46M after 1:25 reverse split."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-258537","json":"https://secwatch.observer/filing/0001193125-24-258537.json","markdown":"https://secwatch.observer/filing/0001193125-24-258537.md","text":"https://secwatch.observer/filing/0001193125-24-258537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/0001193125-24-258537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1419041/000119312524258537/d892744d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:23:37.535579+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}